Shots:

• The P-IIIb ULTIMATE study involves assessing Cosentyx (300/150mg) vs PBO weekly for a mos. with treatment starting @4wks.- followed by a once-a-month dose for the next 11mos. in 166 biologic-naïve patients in a ratio (1:1) with active PsA
• The study reduction of synovitis @12wks. with an early improvement observed as 1wk.- ACR20 (68% vs 34%); ACR50 (46% vs 9%-) & enthesitis (change in SPARCC- -2.4 vs -1.7); safety profile was consistent with previous studies @12wks.
• Cosentyx is the first & only fully-human biologic that directly inhibits IL-17A. Novartis anticipates disclosing full 24-week data from the ongoing ULTIMATE trial at the EULAR in 2021 and final analysis at ACR 2021

  Ref: Novartis | Image: Novartis